au.\*:("SATURN Investigators")
Results 1 to 1 of 1
Selection :
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyCOUDERT, B; CIULEANU, T; PARK, K et al.Annals of oncology. 2012, Vol 23, Num 2, pp 388-394, issn 0923-7534, 7 p.Article
